Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioArctic | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 16.17B | -69.5x | 0.38 | SEK 183.30 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioInvent International | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.90B | -7.1x | 0.23 | SEK 43.85 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Egetis Therapeutics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.24B | -5.7x | -0.3 | SEK 6.24 | 9.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hansa Biopharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.13B | -2.8x | -0.1 | SEK 31.38 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Devyser Diagnostics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.04B | -30.8x | 1.31 | SEK 124 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.7% Upside | Upgrade to Pro+ | |
Vicore Pharma Holding AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.83B | -4.4x | -0.23 | SEK 7.73 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cereno Scientific | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.67B | -22.4x | 0.39 | SEK 5.94 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Diamyd Medical | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.57B | -9.4x | 1.15 | SEK 15.04 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
XSpray Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.52B | -5.7x | 1.11 | SEK 45.10 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nanoform Finland Plc | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.32B | -4.9x | 1.91 | SEK 16.12 | 4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intellego Technologies AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.21B | 13.8x | 0.15 | SEK 42.30 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nykode Therapeutics | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 858.66M | -1.9x | SEK 13.98 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Saniona AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 798.86M | -8.1x | -0.35 | SEK 7.12 | 10.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -9.6% Downside | Upgrade to Pro+ | |
Hamlet Pharma AB | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 603.95M | -14.5x | 0.67 | SEK 3.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Promimic AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 494.42M | -48.5x | 2.8 | SEK 27.50 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mendus AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 453.19M | -3x | -0.05 | SEK 9 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SynAct Pharma AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 423.29M | -2.1x | -0.18 | SEK 10.15 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Initiator Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 402.14M | -23.4x | SEK 7.15 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Curasight AS | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 377.63M | -7.2x | 0.49 | SEK 18.06 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Peptonic Medical | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 345.56M | -0.4x | -0.01 | SEK 0.004 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cantargia AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 334.31M | -1.7x | -0.04 | SEK 1.80 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oncopeptides | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 331.82M | -0.7x | -0.05 | SEK 1.54 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alzinova | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 331.70M | -10.9x | -0.77 | SEK 3.72 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascelia Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 304.66M | -1.6x | -0.07 | SEK 2.97 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medivir B | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 296.12M | -0.1 | SEK 2.63 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Xbrane Biopharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 260.01M | -0.4x | -0.01 | SEK 0.17 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Guard Therapeutics | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 255.73M | -2.5x | -0.08 | SEK 20.80 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Annexin Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 244.64M | -3.2x | -0.12 | SEK 0.46 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biovica International | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 239.87M | -1.6x | -0.04 | SEK 2.74 | 9.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abliva AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 225.66M | -1.9x | -0.2 | SEK 0.14 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |